Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Roberto Costante, Azzurra Stefanucci, Simone Carradori, Ettore Novellino & Adriano Mollica. (2015) DPP-4 inhibitors: a patent review (2012 – 2014). Expert Opinion on Therapeutic Patents 25:2, pages 209-236.
Read now
Read now
Robert J. Greene, Hua Tu, John P. Gibbs & J. Greg Slatter. (2011) Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Xenobiotica 41:11, pages 945-957.
Read now
Read now
Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2011) Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Current Medical Research and Opinion 27:9, pages 1781-1792.
Read now
Read now
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
Articles from other publishers (27)
Marija Drakul, Sergej Tomić, Marina Bekić, Dušan Mihajlović, Miloš Vasiljević, Sara Rakočević, Jelena Đokić, Nikola Popović, Dejan Bokonjić & Miodrag Čolić. (2023) Sitagliptin Induces Tolerogenic Human Dendritic Cells. International Journal of Molecular Sciences 24:23, pages 16829.
Crossref
Crossref
Abeer Rashad Derar, Neven Ahmed & Emad Mohamed Hussien. (2023) A new strategy for the determination of the antidiabetics alogliptin, saxagliptin and vildagliptin using all-solid state potentiometric sensors. BMC Chemistry 17:1.
Crossref
Crossref
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan & J. Chimakurthy. (2023) Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. Journal of Endocrinological Investigation 46:5, pages 855-867.
Crossref
Crossref
Sheila Owens-Collins. 2023. Beta-Cells in Health and Disease [Working Title]. Beta-Cells in Health and Disease [Working Title].
Jiuxiang Liu, Qiang Zuo, Zhi Li, Jiangqi Chen & Feng Liu. (2021) Trelagliptin ameliorates IL-1β-impaired chondrocyte function via the AMPK/SOX-9 pathway. Molecular Immunology 140, pages 70-76.
Crossref
Crossref
Pranav Shah, Kejal Chavda, Bhavin Vyas & Shailaja Patel. (2020) Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Delivery and Translational Research 11:3, pages 1166-1185.
Crossref
Crossref
I. V. Glinkina, A. V. Balashova, A. S. Shyman, A. V. Oderij, S. A. KhanG. E. Runova, T. B. Morgunova & V. V. Fadeev. (2021) Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus. Meditsinskiy sovet = Medical Council:7, pages 56-67.
Crossref
Crossref
Guang Wang, Bing Wu, Lening Zhang, Xuefei Jin, Kun Wang, Wenzhou Xu, Bo Zhang & Heyuan Wang. (2021) The protective effects of trelagliptin on high‐fat diet‐induced nonalcoholic fatty liver disease in mice. Journal of Biochemical and Molecular Toxicology 35:4.
Crossref
Crossref
Amal M Mohamad, Cenk A Andac & Sena Caglar Andac. (2020) Cross Referencing 2D-LC Determination of Intact Gliptins in Urine. Journal of Chromatographic Science 58:10, pages 907-914.
Crossref
Crossref
Richard Ofori-Asenso, Jenni Ilomaki, K.L. Chin, Mohsen Mazidi, Ella Zomer, J.S. Bell, Dianna J. Magliano & Danny Liew. (2019) Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice 158, pages 107909.
Crossref
Crossref
E. V. Biryukova. (2019) Clinical aspects and prospects of using DPP-4 inhibitors. Medical Council:4, pages 24-29.
Crossref
Crossref
Ola M. Abdalla, Ahmed M. Abdel-Megied, Ahmed S. Saad & Shymaa S. Soliman. (2018) Simultaneous spectrophotometric determination of compounds having relatively disparate absorbance and concentration ranges; application to antidiabetic formulation of linagliptin and metformin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 203, pages 112-117.
Crossref
Crossref
Piyush Agarwal, Chhavi Jindal & Vinayak Sapakal. (2018) Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: A randomized, double-blind study. Indian Journal of Endocrinology and Metabolism 22:1, pages 41.
Crossref
Crossref
Antonio Riva, Melissa Laird, Armanda Casrouge, Arvydas Ambrozaitis, Roger Williams, Nikolai V. Naoumov, Matthew L. Albert & Shilpa Chokshi. (2014) Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 60:2, pages 487-496.
Crossref
Crossref
Charbel Abi Khalil & Shahrad Taheri. 2014. Molecular Mechanisms Underpinning the Development of Obesity. Molecular Mechanisms Underpinning the Development of Obesity
179
194
.
Maciej Sałaga, Marta Sobczak & Jakub Fichna. (2013) Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discovery Today 18:15-16, pages 708-715.
Crossref
Crossref
E. Araki, R. Kawamori, N. Inagaki, H. Watada, N. Hayashi, Y. Horie, A. Sarashina, S. Thiemann, M. von Eynatten, K. Dugi & H.‐J. Woerle. (2012) Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 15:4, pages 364-371.
Crossref
Crossref
Thomas Rauch, Ulrike Graefe-Mody, Carolyn F. Deacon, Arne Ring, Jens J. Holst, Hans-Juergen Woerle, Klaus A. Dugi & Tim Heise. (2012) Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy 3:1.
Crossref
Crossref
Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama & K. Kaku. (2012) Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Diabetes, Obesity and Metabolism 14:10, pages 927-936.
Crossref
Crossref
T. Haak, T. Meinicke, R. Jones, S. Weber, M. von Eynatten & H.‐J. Woerle. (2012) Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes, Obesity and Metabolism 14:6, pages 565-574.
Crossref
Crossref
Pradip Jadav, Rajesh Bahekar, Shailesh R. Shah, Dipam Patel, Amit Joharapurkar, Samadhan Kshirsagar, Mukul Jain, Mubeen Shaikh & Kalapatapu V.V.M. Sairam. (2012) Long-acting peptidomimetics based DPP-IV inhibitors. Bioorganic & Medicinal Chemistry Letters 22:10, pages 3516-3521.
Crossref
Crossref
Holger Fuchs, Frank Runge & Heinz-Dieter Held. (2012) Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. European Journal of Pharmaceutical Sciences 45:5, pages 533-538.
Crossref
Crossref
D. R. Owens, R. Swallow, K. A. Dugi & H. J. Woerle. (2011) Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabetic Medicine 28:11, pages 1352-1361.
Crossref
Crossref
R. Gomis, R.-M. Espadero, R. Jones, H. J. Woerle & K. A. Dugi. (2011) Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism 13:7, pages 653-661.
Crossref
Crossref
S. Del Prato, A. H. Barnett, H. Huisman, D. Neubacher, H.-J. Woerle & K. A. Dugi. (2011) Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity and Metabolism 13:3, pages 258-267.
Crossref
Crossref
Rudy Bilous & Richard Donnelly. 2010. Handbook of Diabetes. Handbook of Diabetes
79
86
.
B. Gallwitz & H.‐U. Häring. (2009) Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, pages 1-11.
Crossref
Crossref